{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:02:52Z","timestamp":1773478972981,"version":"3.50.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.critrevonc.2019.102815","type":"journal-article","created":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T10:47:47Z","timestamp":1570272467000},"page":"102815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Emerging therapies in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"144","author":[{"given":"Marika","family":"Cinausero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Rihawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cortiula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Follador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"Fasola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.102815_bib0005","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1158\/1078-0432.CCR-07-0883","article-title":"Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors","volume":"13","author":"Ali","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","article-title":"Immunotherapy and radiation therapy for malignant pleural mesothelioma","volume":"6","author":"Alley","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0020","article-title":"WOG S0905: a randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma","volume":"36","author":"Anne","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0025","series-title":"Pemetrexed Disodium\/Observation in Treating Patients W\/ Malignant Pleural Mesothelioma w\/Out Progressive Disease After 1st Line Chemotherapy-","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0030","series-title":"Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin-","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0035","series-title":"Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0040","series-title":"Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0045","series-title":"A Study of BMS-986148 in Patients With Select Advanced Solid Tumors","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0050","series-title":"Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0055","series-title":"A Study of Cetuximab Combined With Cisplatin or Carboplatin\/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0060","series-title":"Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients with Pleural Mesothelioma","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0065","series-title":"A Study of LY3023414 in Participants With Advanced Cancer","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0070","series-title":"Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0075","series-title":"Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0080","series-title":"Ph 2\/3 Study in Subjects With MPM w\/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0085","series-title":"A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed\/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma","author":"Anon","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0090","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0095","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q","article-title":"Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer task Force (FONICAP) Phase II study","volume":"67","author":"Ardizzoni","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2005.05.007","article-title":"A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma","volume":"50","author":"Berghmans","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0120","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0140","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1245\/s10434-011-1728-x","article-title":"Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma","volume":"18","author":"Cao","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0160","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0165","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A feasibility study evaluating Surgery for Mesothelioma after Radiation Therapy: the \u201cSMART\u201d approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0190","doi-asserted-by":"crossref","DOI":"10.21037\/jtd.2017.10.19","article-title":"Chemotherapy treatment in malignant pleural mesothelioma: a difficult history","volume":"10","author":"Cinausero","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0200","article-title":"COMMAND: a phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed\/platinum therapy","volume":"325s","author":"Dean Anthony Fennell PB","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0210","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.329","article-title":"OA 02.02 ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study","volume":"12","author":"Disselhorst","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0215","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I study of apitolisib (GDC-0980), dual Phosphatidylinositol-3-Kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0225","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0235","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/cncr.11405","article-title":"Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study","volume":"97","author":"Favaretto","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0240","first-page":"75","article-title":"Hippo\/YAP pathway for targeted therapy","volume":"3","author":"Felley-Bosco","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.22366","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2003.05.123","article-title":"Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study","volume":"21","author":"Fizazi","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"620\u20136","key":"10.1016\/j.critrevonc.2019.102815_bib0255","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0260","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1541-7786.MCR-16-0256","article-title":"Dual PI3K\/mTOR inhibition in colorectal cancers with APC and PIK3CA mutations","volume":"15","author":"Foley","year":"2017","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0265","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","article-title":"Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors","volume":"33","author":"Fujisaka","year":"2015","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0270","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0275","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0280","doi-asserted-by":"crossref","first-page":"S1883","DOI":"10.1016\/j.jtho.2017.09.634","article-title":"MA 19.01 a phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT)","volume":"12","author":"Goto","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0285","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8567","article-title":"Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hT","volume":"36","author":"Gregorc","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0295","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0300","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus Pemetrexed\/Cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8569","article-title":"A real-world experience of nivolumab in advanced malignant mesothelioma (MM)","volume":"36","author":"Hamad","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0310","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0315","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0320","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0325","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0330","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0335","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0340","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1245\/s10434-015-4965-6","article-title":"Malignant peritoneal mesothelioma: characterization of the inflammatory response in the tumor microenvironment","volume":"23","author":"Judge","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","article-title":"Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)","volume":"60","author":"Kalmadi","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0350","doi-asserted-by":"crossref","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma","volume":"6","author":"Kanteti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0355","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0360","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MCP.0000000000000489","article-title":"Updates in the diagnosis and treatment of malignant pleural mesothelioma","volume":"24","author":"Katzman","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (CAR) T-Cell therapy for thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0370","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0375","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0380","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0385","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2174\/1389450116666141205160924","article-title":"Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells","volume":"15","author":"Leon","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0395","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","article-title":"Novel systemic therapy against malignant pleural mesothelioma","volume":"6","author":"Mancuso","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0400","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0405","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0410","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.lungcan.2004.11.003","article-title":"Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary","volume":"48","author":"Maziak","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0420","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0425","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0430","first-page":"565","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: a phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014first results","volume":"36","author":"Nowak","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0440","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdj073","article-title":"A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial","volume":"17","author":"O\u2019Brien","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0445","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"O\u2019Brien","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0450","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-4236","article-title":"Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy","volume":"75","author":"Pachter","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0455","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0460","first-page":"63","article-title":"Modern management of malignant pleural mesothelioma","volume":"7","author":"Patel","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0465","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","article-title":"The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma","volume":"15","author":"Pignochino","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0470","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0475","article-title":"OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies","volume":"12","author":"Quispel-Janssen","year":"2019","journal-title":"J Thorac OncolJ. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0480","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0485","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0490","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) As part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0495","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0500","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0505","article-title":"PL02.09 Nintedanib + Pemetrexed\/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial","author":"Scagliotti","year":"2019","journal-title":"Presented at WCLC 2018 19th World Conference Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0510","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12199-007-0015-8","article-title":"Molecular biology of malignant mesothelioma","volume":"13","author":"Sekido","year":"2008","journal-title":"Environ. Health Prev. Med."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0515","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"S-HI","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","article-title":"A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors","volume":"77","author":"Shimizu","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0525","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1081\/CNV-120003538","article-title":"Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma","volume":"20","author":"Skubitz","year":"2002","journal-title":"Cancer Invest."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0530","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0535","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0540","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Toyokawa","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0545","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0550","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0555","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0560","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0565","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0570","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0575","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0580","first-page":"2626","article-title":"Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?","volume":"17","author":"Vogelzang","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0585","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0590","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","author":"Woodard","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0595","doi-asserted-by":"crossref","first-page":"325","DOI":"10.21037\/tlcr.2017.06.03","article-title":"Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma","volume":"6","author":"Wu","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0600","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-014-1597-9","article-title":"Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma","volume":"63","author":"Wu","year":"2014","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0605","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0610","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0615","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SLA.0000000000001908","article-title":"PI3K\/mTOR dual inhibitor, LY3023414, demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model","volume":"266","author":"Zaidi","year":"2017","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0620","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.102815_bib0625","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.074","article-title":"LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial","volume":"28","author":"Zalcman","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0630","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0635","article-title":"Targeting YAP in malignant pleural mesothelioma","author":"Zhang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0640","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2017.06.052","article-title":"Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo","volume":"490","author":"Zou","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2019.102815_bib0645","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer Amst Neth"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:31:11Z","timestamp":1760902271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818303342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":129,"alternative-id":["S1040842818303342"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102815","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102815"}}